# Risk Evaluation Matrices for Biosafety

An agent-based risk group table classifies the organism, while a procedure-based risk evaluation matrix classifies the work, and that single difference decides which tool protects your staff. The rule of thumb for choosing is straightforward. Use an agent-based table with a basic likelihood-severity grid when every activity with a given organism runs the same way. Move to a procedure-specific matrix when the same organism passes through protocols with very different exposure potential, for example a closed extraction cartridge in one workflow and open-vial subculture in another.

Every biosafety risk assessment needs a scoring step, and that step is the biosafety risk evaluation matrix. Without a consistent scoring scheme, containment decisions drift toward habit, and two technologists can reach different conclusions about the same protocol. A matrix makes the reasoning visible, comparable across activities, and auditable by accreditors, inspectors, and your own safety committee.

## What a Biosafety Risk Evaluation Matrix Does

![Six-step cycle from gathering information through initial risk, controls, implementation, residual risk and scheduled review.](/article-images/illustrations/biosafety-risk-evaluation-matrix-assessment-cycle.webp)

A biosafety risk assessment is the structured process of identifying what can cause harm during work with biological agents, judging how likely and how severe that harm would be, applying controls, and judging what risk remains. The matrix is the scoring instrument inside that process. Risk evaluation matrices for biosafety all share this purpose, and they differ mainly in what they score, the agent, the procedure, or the management system around both.

A few terms appear in every matrix, so they need definitions before the options make sense.

- **Hazard.** The source of potential harm, such as a pathogen, a toxin, or an unwashed specimen.
- **Likelihood.** The probability that an exposure or release event occurs during the activity.
- **Consequence.** The severity of the impact if the event occurs, ranging from a contained minor exposure to serious infection or an environmental release.
- **Exposure.** The route and degree of contact with the agent, most often inhalation of aerosols, splashes to mucous membranes, percutaneous injury, or ingestion.
- **Risk group (RG).** A hazard classification of the organism itself, assigned on a four-level scale in most national and international schemes.
- **[Biosafety level](/knowledge/diagnostics/emerging-tech/biosafety-levels-1-4-a-comparative-framework-for-diagnostic-laboratory-design) (BSL).** The combination of laboratory practices, safety equipment, and facility features assigned to the work.
- **Residual risk.** The risk that remains after controls are applied, scored on the same scale as the initial risk so the effect of each control is visible.

Laboratory biosafety risk assessment is dynamic and systematic work, and its scope covers pathogenic microbial hazards, experimental activities, facilities and equipment, personnel, and experimental methods [1]. Formal methodologies designed to make this evaluation repeatable across facilities have existed since at least 2010, when a structured biosafety risk assessment methodology was published to standardize how hazards, likelihoods, and consequences are combined [2]. The fourth edition of the World Health Organization (WHO) Laboratory [Biosafety Manual](/knowledge/diagnostics/emerging-tech/biosafety-manual-development-a-template-for-diagnostic-laboratories) later placed risk assessment at the center of laboratory biosafety, and national training programs have since been built to transfer those concepts into daily bench practice [3].

The assessment cycle that most modern matrices support runs in six steps.

1. Gather information on the agent, the procedure, the people, and the facility.
2. Evaluate the risk before controls, called the initial risk.
3. Develop a control strategy following the hierarchy of controls, which ranks elimination, substitution, engineering controls, administrative controls, and personal protective equipment from most to least effective.
4. Implement the selected controls.
5. Reassess to quantify residual risk.
6. Review and update on a defined schedule and after trigger events such as incidents, equipment changes, or new guidance.

The matrix never replaces judgment. It records judgment in a form that others can check, challenge, and update.

## Biosafety Risk Evaluation Matrix Options at a Glance

Six options cover nearly every real-world need, from a teaching inventory to a pandemic-era diagnostic laboratory.

| Matrix option | Core question | Typical output | Best fit | Main limitation |
|--|--|--|--|--|
| Agent-based risk group table | How dangerous is the organism? | Risk group (RG1 to RG4) mapped to a starting biosafety level | Inventory screening, teaching, first-pass triage | Blind to what the procedure does to exposure |
| Likelihood-severity grid | How likely and how bad is each hazard? | Banded score (low, medium, high) | Facility hazards, spills, sharps, equipment failure | Ordinal scores invite arithmetic the numbers do not support |
| Structured qualitative assessment (WHO 4th edition style) | What is the risk before and after controls? | Initial risk and residual risk per activity | Clinical and diagnostic laboratories | Documentation-heavy, quality depends on assessor judgment |
| Procedure-specific risk (PSR) matrix | What exposure does this protocol generate? | Biosafety level assignment per procedure | Viral vectors, GMOs, multistep research protocols | More effort per protocol, needs trained assessors |
| Management-system gap analysis | Does the program meet a standard clause by clause? | Gap list with corrective actions | Hospital and institute programs, accreditation | Does not score individual experiments |
| Continuous monitoring with safety indicators | Are the controls still working? | Trend data with trigger thresholds | High-throughput and pandemic-era laboratories | Requires indicator design and review discipline |

No single option is the best biosafety risk evaluation matrix in the abstract. The right choice depends on the regulatory driver, the diversity of procedures, the training level of staff, and whether the assessment must defend a containment decision or simply rank a list of hazards. Each option is explained on its own terms below, with the pros and cons that decide real choices.

## Option 1: Agent-Based Risk Group Tables

This is the oldest and most widely taught approach. The organism is assigned to a risk group, and a starting biosafety level is read from a table. The four-level evaluation method for pathogenic microorganisms remains the standard hazard assessment tool in biosafety laboratory risk assessment [1].

In the conventional scheme, risk group 1 agents pose low individual and community risk, risk group 2 agents pose moderate individual risk with limited community risk, risk group 3 agents pose high individual risk with low community risk, and risk group 4 agents pose high individual and community risk and require the highest containment available. The two dimensions matter separately, because an agent can be dangerous to the person handling it yet unlikely to spread in the community.

**Pros**

- Fast and reproducible, since two trained staff usually assign the same group to the same organism.
- Ideal for inventory screening, because every strain on the shelf can be triaged in minutes.
- Teaches the shared vocabulary of biosafety, which makes it a fixture of microbiology biosafety training.

**Cons**

- Blind to procedure. A risk group table cannot distinguish a sealed diagnostic assay from open-vial subculture of the same agent.
- Blind to dose and volume, even though concentration changes outcomes for some organisms.
- Invites the assumption that a risk group automatically equals a biosafety level. Modern frameworks reject that shortcut, because exposure generated by the procedure, rather than agent taxonomy alone, determines containment needs [4].

Use this option as the starting layer of every assessment, never as the whole assessment.

## Option 2: Likelihood-Severity Grids

The classic risk matrix is a grid. Hazards are listed, each hazard is rated for likelihood and consequence, and the two ratings combine into a band. A 3 by 3 grid produces nine cells and suits small facilities. A 5 by 5 grid produces twenty-five cells and gives finer separation for large programs. Bands carry standard actions. Low risks are accepted and monitored, medium risks are reduced with controls, and high risks stop the activity until engineering or procedural changes bring them down.

The grid only works when every level has a written anchor definition. Many programs use five likelihood levels running from rare through almost certain, and five consequence levels running from negligible through catastrophic, with each level described in plain words tied to the laboratory's own incident history. An illustrative middle anchor for likelihood is "possible, has occurred in comparable laboratories," and a middle anchor for consequence is "medical treatment required with lost work time."

A worked example shows the mechanics. A broken centrifuge rotor with an aerosol release from a risk group 2 organism is scored as possible likelihood with moderate consequence, which lands in the medium band. Controls such as sealed rotors, loading rules, and a hold period before opening convert the score to a low residual band. The specific band boundaries are set locally, and the grid itself does not dictate them.

**Pros**

- Covers non-biological hazards that agent tables ignore, including sharps, electrical faults, and chemical spills.
- Communicates well to management, because a banded chart is easier to defend than a paragraph.
- Fast enough to run for an entire facility in one afternoon.

**Cons**

- The numbers are ordinal, so a score of 16 is not twice a score of 8, and averaging across cells produces nonsense.
- Band boundaries are arbitrary, and different laboratories draw them differently.
- Scoring from memory rather than from incident data inflates or deflates results, and two assessors can disagree unless anchors are fixed.

The grid works best with two assessors scoring independently before comparing results, and with annual recalibration against actual incidents and near misses.

## Option 3: Structured Qualitative Assessment With Residual Risk

The fourth edition of the WHO Laboratory Biosafety Manual replaced the one-agent-one-level habit with a cycle. The assessor gathers information, evaluates the risk, develops a control strategy, implements the controls, then reassesses to quantify residual risk. National implementation programs have been built around exactly these concepts, including a structured training and rollout effort in Pakistan that moved the fourth edition approach into working laboratories [3].

Information gathering is the step most often rushed. A defensible record captures four things. First, agent facts, including pathogenicity, route of transmission, stability outside the host, and available treatment. Second, procedure facts, including each step, volumes handled, equipment used, and which steps generate aerosols. Third, people facts, including training, demonstrated competency, and immunization status where relevant. Fourth, facility facts, including airflow direction, biological safety cabinet type, and decontamination capacity.

The defining feature of this option is the paired score. Every activity carries an initial risk before controls and a residual risk after controls, and both are recorded on the same scale. That pairing shows whether the control package actually moved the risk, and it gives management a defensible basis for accepting what remains.

**Pros**

- Matches the structure of modern guidance, so assessments translate directly into accreditation documents.
- Flexible across specimen types, which matters in [clinical microbiology](/knowledge/diagnostics/microbiology/clinical-microbiology-from-specimen-collection-to-pathogen-identification) where the workload changes weekly.
- Produces an auditable trail from hazard to control to residual score.

**Cons**

- Judgment-dependent, so the same protocol can score differently under different assessors unless anchors and templates are fixed.
- Slower than a grid, because each activity needs its own record.
- Documentation grows quickly in high-complexity laboratories, and stale records erode trust in the whole system.

This option is the default recommendation for clinical and diagnostic microbiology laboratories.

## Option 4: Procedure-Specific Risk (PSR) Matrices

Procedure-specific frameworks answer the question that agent tables cannot. The exposure generated by the procedure, rather than the taxonomy of the agent, serves as the primary determinant of containment. One published framework formalizes this as an 8-step operational protocol that integrates agent risk group classification, procedural exposure characterization, and modulating factor evaluation into a biosafety level assignment matrix, supported by a structured assessment template and a freely accessible digital implementation tool [4].

The same framework was built through comparative analysis of ten national and international reference documents, including the WHO Laboratory Biosafety Manual 4th edition, the US Biosafety in Microbiological and Biomedical Laboratories (BMBL) 6th edition, and the CDC Biological Risk Assessment guidance, and its biosafety level assignments show content and convergent validity against those sources [4]. Modulating factors, meaning items such as staff training, immunization status, agent quantity, and concentration, adjust the score after the procedure itself is characterized.

Concrete examples show why procedure beats taxonomy. Sequencing extracted nucleic acid from a risk group 3 organism generates far less exposure than subculturing that same organism, and a framework keyed to the agent alone cannot express that difference. Producing [lentiviral vector](/knowledge/molecular-biology/lentiviral-vector) and transducing a cell line with purchased vector carry different exposure profiles even though both involve the same vector backbone.

**Pros**

- Reproducible assignments, because the same protocol scored by different assessors converges on the same biosafety level.
- Handles the modern reality of viral vectors, genetically modified organisms, and multistep protocols that a single agent label cannot describe.
- Defensible to regulators, since the reasoning chain from exposure to containment is explicit.

**Cons**

- More effort per protocol, which is real cost in a busy laboratory.
- Requires assessors trained in exposure characterization, not just in agent facts.
- Newer frameworks have fewer local precedents, so early adopters carry some interpretation burden.

Choose this option when the same agent moves through protocols with sharply different exposure profiles, or when your portfolio includes vectors and recombinant constructs.

## Option 5: Management-System Gap Analysis and Audit Checklists

Gap analysis works at the program level rather than the experiment level. The laboratory is audited clause by clause against a management standard, and every shortfall becomes a risk factor with a corrective action, an owner, and a due date.

Two published applications show the pattern. In eight COVID-19 reference hospitals across Sumatra, Kalimantan, and Java, checklist forms referencing ISO 35001:2019 were used to evaluate laboratory bio-risk management systems, and gap analysis across the seven clauses of the standard revealed the largest shortfalls in leadership, support, and performance [5]. In Jiaxing, China, inspectors used the local standard DB33/T 2540 for biosafety quality control inspection and risk identification, together with the industry standard RB/T 040 for risk analysis and assessment, across 2021 to 2023 [6]. Problems clustered in organization management at 39.76 percent and laboratory housekeeping at 28.97 percent of findings, and nonstandard use of biosafety labels became increasingly prominent over the three years, while every identified risk factor was rated at medium or low, leaving the overall laboratory biosafety risk level controllable and acceptable [6].

**Pros**

- Covers the whole program, including training records, documentation, signage, and waste flows that experiment-level matrices never see.
- Produces audit-ready output that accreditors recognize.
- Tracks improvement over years when repeated on a fixed schedule.

**Cons**

- Does not score individual experiments, so a laboratory can pass an audit while running an under-contained assay.
- Degrades into a checkbox exercise when findings are logged without root-cause analysis.
- Standard-specific, so results do not transfer between frameworks without mapping.

Pair gap analysis with an activity-level matrix, since the two cover each other's blind spots.

## Option 6: Continuous Risk Monitoring and Safety Indicators

A matrix scores risk at a moment. Monitoring asks whether the score is still true next month. A clinical laboratory in China built its biosafety management around risk assessment, risk response, and risk monitoring, and published its experience from before and during the COVID-19 epidemic [7]. Before the pandemic, the laboratory identified 30 unacceptable risks and implemented control measures, after which residual risks were acceptable and no biosafety incidents occurred. During the pandemic, repeated monitoring identified 10 new risks, 3 ineffective control measures, and multiple instances of excessive protection, and control measures were adjusted in time to prevent personnel infection while avoiding overprotection [7].

Safety indicators are the instruments of this option. An indicator is a measurable value tracked over time, such as audit findings per quarter, exposure incident reports, spill counts, training completion rates, or the number of risk assessments past their review date. Each indicator carries a threshold that triggers reassessment, and the indicator set is reviewed on a fixed cadence.

**Pros**

- Catches drift that a one-time matrix cannot, including controls that quietly stop working.
- Right-sizes protection, since monitoring exposed both ineffective measures and excessive protection in the same program [7].
- Gives leadership objective trend data instead of anecdotes.

**Cons**

- Requires indicator design, data collection, and a review cadence that someone must own.
- Poorly chosen indicators measure paperwork instead of safety.
- Adds meetings, which laboratories resist unless leadership enforces them.

## How to Choose Between Biosafety Risk Evaluation Matrix Options

![Decision path asking about program-level scope, procedure diversity and reproducibility needs to pick a matrix option.](/article-images/illustrations/biosafety-risk-evaluation-matrix-choosing-matrix.webp)

Six criteria decide the choice in practice.

1. **Regulatory driver.** Accreditation programs expect documented initial and residual risk per activity, which points to the structured qualitative option. Internal improvement programs can start with a grid.
2. **Procedure diversity.** One agent with one workflow suits an agent table plus a grid. One agent with many workflows demands a procedure-specific matrix [4].
3. **Reproducibility needs.** If assignments must survive inspection or multi-site harmonization, prefer frameworks with published validation and explicit scoring steps [4].
4. **Training capacity.** Every option assumes trained users. Structured microbiology biosafety training built on the fourth edition concepts is the entry requirement for the qualitative and procedure-specific options [3].
5. **Scope.** Program-level questions, such as leadership and documentation, belong to gap analysis [5]. Activity-level questions belong to grids and structured assessments.
6. **Rate of change.** When the workload shifts fast, as it did when laboratories worldwide reprioritized toward SARS-CoV-2 work during the pandemic, event-driven reassessment must supplement the calendar.

Two cross-cutting lessons tighten the choice. Multi-lab benchmarking works, as shown by a statewide risk assessment of clinical laboratories that process specimens for microbiologic analysis, which used a shared instrument to raise the culture of biosafety across a whole region [8]. And case-specific beats one-size-fits-all, a principle confirmed in the plant [genome editing](/blog/guides/genome-editing) field, where the European Food Safety Authority found the existing environmental risk assessment framework suitable but requiring case-specific application [9].

## Worked Scenarios

### Scenario 1: A Diagnostic Parasitology Laboratory During the COVID-19 Pandemic

A routine diagnostic parasitology laboratory at a tertiary care center used the risk assessment template from the WHO interim guidance on laboratory biosafety related to COVID-19 to assess two processes, diagnosis of protozoan diseases in respiratory tract samples and diagnosis of intestinal parasitic diseases [10]. The overall initial risk for both processes was very high. The controls were decisive and specific. Fresh microscopic examination steps in both processes and the concentration steps for intestinal parasite diagnosis were discontinued, and all aerosol-generating steps were moved into a Class IIA biological safety cabinet. The overall residual risk fell to medium for both processes [10]. The lesson is that a matrix earns its keep when it drives concrete stop and move decisions rather than filing.

### Scenario 2: A Tuberculosis Mycobacteriology Laboratory Network

Occupational tuberculosis among mycobacteriology workers has received insufficient attention in high-burden settings, so a descriptive study in two Nigerian states scored its tuberculosis laboratories with a semi-structured questionnaire covering degree of exposure, viability of bacilli, aerosol generation, laboratory configuration, typology, and fitness of staff to work in the laboratory, with results categorized as low, moderate, or high risk [11]. Of 64 laboratory health workers, 58 participated, and the calculated risk for occupational tuberculosis was low for 55 participants (94.8 percent) and moderate for 3 (5.2 percent), with no respondent in the high category [11]. The lesson is that a questionnaire-based scoring instrument works where formal biosafety staffing is thin, and the output is a ranked list that directs corrective spending.

### Scenario 3: A Recombinant Remediation Strain Headed for Environmental Use

Environmental application adds release and dose rows to the matrix. A chromium-removal recombinant strain, 3458, was evaluated through a subacute toxicity test in mice with gut microbiome analysis, modeling fecal-oral exposure [12]. At 1.0 × 10^11 CFU/mL, the strain induced liver damage and affected renal function and lipid metabolism, with part of the toxicity signal attributed to the pET-28a carrier, and prolonged exposure raised the risk of increasing pathogenic bacteria [12]. Disinfection validation closed the loop. Chlorine-containing disinfectant at 500 mg/L or chlorine dioxide at 250 mg/L for 30 minutes achieved a sterilization rate above 99.9 percent, supporting the strain's application value in wastewater treatment [12]. The lesson is that dose and disinfection rows changed the verdict, and an agent-only table would have missed both.

### Scenario 4: Transferring a Gene Therapy Process From Research to Manufacturing

Containment can move down as well as up when controls substitute for containment tiers. A risk assessment guide was used to define the risk profile of a theoretical [gene therapy](/blog/guides/gene-therapy) process with a human cell line intended for clinical and commercial manufacture, and the assessment justified downgrading specific Biosafety Level 2 elements to Biosafety Level 1, including facility containment controls, emergency spill response plans, and storage and shipping requirements, because robust contamination controls and current Good Manufacturing Practice principles manage the biohazard risk, while other aspects remained at Biosafety Level 2 due to the severity of the control risk [13]. The companion guidance for commercial-scale cell and gene therapy manufacturing describes the team behind such an assessment, a cross-functional group that characterizes hazards, reviews engineering controls and monitoring systems, and audits site practices from gowning to emergency response [14]. The lesson is that matrices justify downgrades as well as upgrades, and cross-functional scoring prevents single-view bias.

## Common Mistakes and Limitations

1. **Treating risk group as biosafety level.** The direct RG-to-BSL shortcut fails to capture how exposure varies across modern procedures, which is the core finding that motivated procedure-specific frameworks [4].
2. **Writing the assessment once and shelving it.** Biosafety laboratory risk assessment is dynamic and systematic work and should be conducted regularly to ensure safe operation [1].
3. **Forgetting aerosols.** Aerosol exposure is the most common exposure in experimental activities, and a matrix that scores splashes and sharps while skipping aerosol-generating steps misses the dominant route.
4. **Scoring initial risk and stopping.** Without a residual score, nobody can tell whether the controls worked, and the assessment cannot support acceptance decisions.
5. **Doing arithmetic on ordinal scores.** Averaging, multiplying across activities, or ranking 16 against 8 as if the interval were linear produces false precision.
6. **Running gap analysis without activity-level scoring.** A laboratory can satisfy every clause of a management standard and still run an under-contained assay, which is why gap analysis pairs with an experiment-level matrix [5].
7. **Overlooking housekeeping and labels.** In a three-year regional assessment, laboratory housekeeping and nonstandard biosafety label use grew into prominent problem categories, which activity-level scoring alone would not have surfaced [6].
8. **Never checking whether controls still work.** Monitoring in one clinical laboratory found 3 ineffective control measures and multiple instances of excessive protection during the pandemic, and both directions of failure carry cost [7].
9. **Adopting guidance nobody tested.** A multinational effort to endorse risk assessment guidance under the Cartagena Protocol failed after a poorly defined and shifting purpose, misplaced expertise, and a misguided testing process, a reminder that guidance must be validated in working laboratories before it is imposed [15].
10. **Ignoring modulating factors.** Training, immunization, staff health, agent quantity, and concentration change the score, and frameworks that skip them systematically misclassify risk [4].

One limitation applies to every option. Matrix outputs are decision support, not decisions. Final containment assignments in an individual facility should be reviewed by a qualified biosafety professional who knows the local facility, staff, and incident history.

## Frequently Asked Questions

### What is a biosafety risk evaluation matrix?

A biosafety risk evaluation matrix is a scoring table that ranks laboratory hazards by likelihood and consequence so that containment and control decisions are consistent, documented, and comparable across activities. It is the scoring step inside the broader biosafety risk assessment cycle.

### Which is the best biosafety risk evaluation matrix for a clinical microbiology laboratory?

For most clinical microbiology laboratories, a structured qualitative assessment that scores initial and residual risk for each activity, in the style of the WHO Laboratory Biosafety Manual 4th edition, is the best fit. Specimen types and workflows change constantly, and this option flexes with them while producing audit-ready records.

### How often should a biosafety risk assessment be updated?

Update it on a fixed schedule and whenever the agent, procedure, equipment, staffing, or applicable guidance changes. Risk assessment is dynamic and systematic work, not a one-time document.

### What is the difference between a risk group and a biosafety level?

A risk group classifies the hazard of the organism itself on a four-level scale, while a biosafety level describes the containment assigned to the work. The same organism can justify different [biosafety levels](/knowledge/diagnostics/emerging-tech/biosafety-levels-1-4-a-decision-framework-for-diagnostic-laboratories) depending on the procedure, the quantity, and the controls available.

### What does residual risk mean on a matrix?

Residual risk is the risk that remains after controls are in place, scored with the same scale as the initial risk. The pairing shows whether the control package actually moved the risk and gives management a defensible basis for accepting what remains.

### Do I need formal microbiology biosafety training to use a risk matrix?

Simple likelihood-severity grids can be used after short in-house training with written anchor definitions. Defensible biosafety level assignments and standard-based gap analyses require trained assessors, and structured microbiology biosafety training built on fourth edition concepts is the standard entry path.

<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "What is a biosafety risk evaluation matrix?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "A biosafety risk evaluation matrix is a scoring table that ranks laboratory hazards by likelihood and consequence so that containment and control decisions are consistent, documented, and comparable across activities. It is the scoring step inside the broader biosafety risk assessment cycle."
      }
    },
    {
      "@type": "Question",
      "name": "Which is the best biosafety risk evaluation matrix for a clinical microbiology laboratory?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "For most clinical microbiology laboratories, a structured qualitative assessment that scores initial and residual risk for each activity, in the style of the WHO Laboratory Biosafety Manual 4th edition, is the best fit. Specimen types and workflows change constantly, and this option flexes with them while producing audit-ready records."
      }
    },
    {
      "@type": "Question",
      "name": "How often should a biosafety risk assessment be updated?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Update it on a fixed schedule and whenever the agent, procedure, equipment, staffing, or applicable guidance changes. Risk assessment is dynamic and systematic work, not a one-time document."
      }
    },
    {
      "@type": "Question",
      "name": "What is the difference between a risk group and a biosafety level?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "A risk group classifies the hazard of the organism itself on a four-level scale, while a biosafety level describes the containment assigned to the work. The same organism can justify different biosafety levels depending on the procedure, the quantity, and the controls available."
      }
    },
    {
      "@type": "Question",
      "name": "What does residual risk mean on a matrix?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Residual risk is the risk that remains after controls are in place, scored with the same scale as the initial risk. The pairing shows whether the control package actually moved the risk and gives management a defensible basis for accepting what remains."
      }
    },
    {
      "@type": "Question",
      "name": "Do I need formal microbiology biosafety training to use a risk matrix?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Simple likelihood-severity grids can be used after short in-house training with written anchor definitions. Defensible biosafety level assignments and standard-based gap analyses require trained assessors, and structured microbiology biosafety training built on fourth edition concepts is the standard entry path."
      }
    }
  ]
}
</script>

## Sources

1. [Biosafety laboratory risk assessment](https://doi.org/10.1016/J.JOBB.2019.01.011)
2. [Biosafety Risk Assessment Methodology](https://doi.org/10.2172/1325209)
3. [Pakistan’s experience with risk assessment training and implementation of concepts from the 4th edition of the WHO laboratory biosafety manual](https://doi.org/10.1016/j.jobb.2021.09.002)
4. [An 8-step procedure-specific risk framework enables reproducible biosafety level assignment beyond agent-based classification.](https://pubmed.ncbi.nlm.nih.gov/42539660/)
5. [Bio-Risk Management Systems: Biosafety Assessment in COVID-19 Referral Hospitals in Indonesia](https://doi.org/10.3390/safety10020036)
6. [Biosafety status analysis and risk assessment of laboratories from 2021 to 2023 in Jiaxing, China](https://pubmed.ncbi.nlm.nih.gov/40309507/)
7. [Biosafety Management Based Upon Risk Assessment and Monitoring: Perspectives from a Clinical Laboratory, China](https://pubmed.ncbi.nlm.nih.gov/39355057/)
8. [Laboratory Focus on Improving the Culture of Biosafety: Statewide Risk Assessment of Clinical Laboratories That Process Specimens for Microbiologic Analysis](https://pubmed.ncbi.nlm.nih.gov/29118166/)
9. [Biosafety of Genome Editing Applications in Plant Breeding: Considerations for a Focused Case-Specific Risk Assessment in the EU](https://pubmed.ncbi.nlm.nih.gov/35822764/)
10. [Biosafety Risk Assessment of a Routine Diagnostic Laboratory During the Coronavirus Disease 2019 Pandemic](https://pubmed.ncbi.nlm.nih.gov/36032648/)
11. [Risk Assessment of Tuberculosis Laboratories and Biosafety Practices among Laboratory Health Workers in Two Selected States in Nigeria](https://doi.org/10.55320/mjz.45.2.135)
12. [Exploration of risk analysis and elimination methods for a Cr(VI)-removal recombinant strain through a biosafety assessment in mice.](https://pubmed.ncbi.nlm.nih.gov/38007124/)
13. [Environmental Health and Safety Offers a Biosafety Risk Assessment for a Theoretical Model of a Gene Therapy Process Transfer from Research and Development to Large-Scale Manufacturing](https://pubmed.ncbi.nlm.nih.gov/37736419/)
14. [Environmental Health and Biosafety Risk Assessment Guidance for Commercial-Scale Cell and Gene Therapy Manufacturing](https://pubmed.ncbi.nlm.nih.gov/36032393/)
15. [When Policy Meets Practice: The Dilemma for Guidance on Risk Assessment Under the Cartagena Protocol on Biosafety](https://pubmed.ncbi.nlm.nih.gov/31119127/)